1243P - The prognostic significance of Distant Metastasis Free Interval (DMFI) in BRAF mutant advanced melanoma patients treated with first line targeted t...

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Cancer in Adolescents
Melanoma and other Skin Tumours
Personalised Medicine
Presenter Dimitrios Bafaloukos
Citation Annals of Oncology (2017) 28 (suppl_5): v428-v448. 10.1093/annonc/mdx377
Authors D. Bafaloukos1, H. Linardou1, P. Diamantopoulos2, T. Sergentanis3, A. Laskarakis1, K. Giati1, A. Tarampikou1, A. Anastasopoulou2, H. Gogas2
  • 1A' Oncology Dept, Metropolitan Hospital, 18547 - Athens/GR
  • 21st Dept Of Medicine, Laikon Hospital, Medical School, National and Kapodestrian University of Athens, Athens/GR
  • 3Dept Of Hygiene, Epidemiology And Medical Statistics, Medical School, National and Kapodestrian University of Athens, Athens/GR

Abstract

Background

Prognostic models are investigated for advanced melanoma patients treated with targeted therapy. This study aims to identify the relationship between DMFI and outcome of 1st line targeted therapy in BRAF mutant (BRAFmut) patients.

Methods

BRAFmut patients identified from 2 referral centres were assigned to 3 prognostic groups: A (PS 0, Metastatic sites ≤3, LDH normal, CNS not involved), B (PS 1, Metastatic sites ≤3, LDH >1-2ULN, CNS not involved), C (PS 2, Metastatic sites >3, LDH ≥2ULN, CNS involved or not). Factors analysed: Distant Metastasis Free Interval (DMFI from primary melanoma to 1st distant metastasis), Post Relapse Progression Free Survival (PRPFS post relapse to BRAFi), Post Relapse Survival (PRS), number of metastatic sites, LDH, CNS involvement, PS. Univariate and multivariate Cox regression analysis was used adjusted with the 3 prognostic groups. Statistical analysis with STATA/SE V13.0.

Results

From 380 advanced melanoma patients, 161 BRAFmut patients received 1st line BRAFi only (101) or BRAFi+MEKi (60). Patients relapsed from primary at a median DMFI 12 months (range 0-185) and were included in the 3 prognostic groups (Group A 27, Group B 72, Group C 56). To study DMFI significance, we defined 2 patient groups according to DMFI: DMFI

Conclusions

Patients with BRAFmut advanced melanoma and DMFI

Clinical trial identification

Legal entity responsible for the study

A' Oncology Dept, Metropolitan Hospital

Funding

None

Disclosure

All authors have declared no conflicts of interest.